(SPOT.ph) Things are looking up in the battle against the COVID-19 virus. On November 10, pharmaceutical company Pfizer and biotechnology company BioNTech SE announced that BNT162b2, their mRNA-based vaccine candidate for COVID-19, has been found to be more than 90% effective against the virus, specifically for participants of the trial without prior evidence of COVID-19.
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO in a statement. The finding is based on the first interim efficacy analysis conducted on November 8 by an external independent data monitoring committee.
Out of 43,538 trial participants, there have been 94 confirmed cases of COVID-19. Pfizer notes that no serious safety concerns have been observed. The trial will continue until it reaches 164 confirmed cases so that they can collect further data.
The company is on track to file for emergency-use authorization in the U.S. Food and Drug Administration once they achieve the safety milestone required. Currently, this is expected to occur in the third week of November.
Pfizer and BioNTech SE are looking to produce 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.
Hey, Spotters! Check us out on Viber to join our Community and subscribe to our Chatbot.
[ArticleReco:{"articles":["84259","84258","84248","84240"], "widget":"Hot Stories You Might Have Missed"}]
Source: Spot PH
No comments:
Post a Comment